Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)

Phase 2

Active, not recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Sacituzumab Govitecan-hziy (SG)
Drug: Pembrolizumab
Drug: Carboplatin
Drug: Cisplatin

First Posted Date: 2022-01-11

Last Posted Date: 2024-10-21

Lead Sponsor: Gilead Sciences

Target Recruit Count: 193

Registration Number: NCT05186974

Locations: 🇭🇰
Queen Elizabeth Hospital, Hong Kong, Hong Kong
🇲🇾
Institut Kanser Negara, Putrajaya, Malaysia
🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan

and more 98 locations

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Phase 2

Recruiting

Conditions: Hodgkin Lymphoma

Interventions: Drug: Gemcitabine
Drug: Brentuximab vedotin
Drug: Dexamethasone
Drug: Pembrolizumab
Drug: Cisplatin

First Posted Date: 2022-01-06

Last Posted Date: 2024-11-08

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 84

Registration Number: NCT05180097

Locations: 🇦🇺
Austin Hospital, Heidelberg, Victoria, Australia
🇨🇦
Verspeeten Family Cancer Centre, London, Ontario, Canada
🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada

and more 10 locations

Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients

Phase 2

Recruiting

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Cisplatin
Drug: Nab-paclitaxel
Drug: Pembrolizumab
Drug: Olaparib

First Posted Date: 2022-01-03

Last Posted Date: 2023-09-28

Lead Sponsor: Fudan University

Target Recruit Count: 136

Registration Number: NCT05174832

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

Phase 3

Active, not recruiting

Conditions: Endometrial Neoplasms

Interventions: Biological: pembrolizumab
Drug: carboplatin
Drug: paclitaxel
Drug: docetaxel
Drug: cisplatin

First Posted Date: 2021-12-30

Last Posted Date: 2024-11-21

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 280

Registration Number: NCT05173987

Locations: 🇺🇸
Northside Hospital ( Site 0017), Atlanta, Georgia, United States
🇺🇸
St. Dominic's Hospital ( Site 0024), Jackson, Mississippi, United States
🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0026), Hackensack, New Jersey, United States

and more 192 locations

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

Phase 1

Recruiting

Conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Head and Neck Carcinoma of Unknown Primary
Locally Advanced Head and Neck Squamous Cell Carcinoma
Locally Advanced Hypopharyngeal Squamous Cell Carcinoma
Locally Advanced Laryngeal Squamous Cell Carcinoma
Locally Advanced Nasal Cavity Squamous Cell Carcinoma
Locally Advanced Oral Cavity Squamous Cell Carcinoma
Locally Advanced Oropharyngeal Squamous Cell Carcinoma
Locally Advanced Paranasal Sinus Squamous Cell Carcinoma
Locally Advanced Sinonasal Squamous Cell Carcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Biopsy
Drug: Cisplatin
Procedure: Computed Tomography
Drug: Ipatasertib
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Radiation: Radiation Therapy

First Posted Date: 2021-12-29

Last Posted Date: 2024-10-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 46

Registration Number: NCT05172245

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
University of Kansas Clinical Research Center, Fairway, Kansas, United States

and more 13 locations

JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma

Phase 2

Recruiting

Conditions: Esophageal Small Cell Carcinoma

Interventions: Drug: JS001
Drug: nab-paclitaxel
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2021-12-29

Last Posted Date: 2023-06-27

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 43

Registration Number: NCT05173246

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Pathological Response After Neoadjuvant Treatment on NSCLC

Recruiting

Conditions: Stage IIIA Non-small Cell Lung Cancer

Interventions: Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2021-12-22

Last Posted Date: 2024-08-19

Lead Sponsor: Fundación GECP

Target Recruit Count: 150

Registration Number: NCT05167487

Locations: 🇪🇸
Hospital Universitario Insular de Gran canaria, Las Palmas De Gran Canaria, Gran Canaria, Spain
🇪🇸
Hospital Vall d'Hebron, Barcelona, Spain
🇪🇸
Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain

and more 14 locations

Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial

Phase 2

Withdrawn

Conditions: Extensive Stage Lung Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8

Interventions: Drug: Carboplatin
Drug: Cisplatin
Biological: Durvalumab
Drug: Etoposide
Radiation: Hypofractionated Radiation Therapy
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2021-12-17

Last Posted Date: 2023-10-18

Lead Sponsor: University of Washington

Registration Number: NCT05161533

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

Phase 2

Recruiting

Conditions: Recurrent Head and Neck Squamous Cell Carcinoma
Metastatic Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Camrelizumab
Drug: Apatinib Mesylate
Drug: Cisplatin
Drug: Docetaxel
Drug: Carboplatin

First Posted Date: 2021-12-14

Last Posted Date: 2021-12-14

Lead Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Target Recruit Count: 178

Registration Number: NCT05156970

Locations: 🇨🇳
the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Phase 3

Recruiting

Conditions: Gastric Neoplasms
Gastroesophageal Adenocarcinoma
Esophageal Adenocarcinoma

Interventions: Drug: Zanidatamab
Drug: Trastuzumab
Drug: Capecitabine
Drug: Tislelizumab
Drug: Oxaliplatin
Drug: Cisplatin
Drug: 5-Fluorouracil

First Posted Date: 2021-12-09

Last Posted Date: 2024-12-24

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 918

Registration Number: NCT05152147

Locations: 🇦🇷
Hospital de Gastroenterología Dr Bonorino Udaondo, Buenos Aires, Argentina
🇦🇷
Fundación Centro de Medicina Nuclear y Molecular ER, Córdoba, Argentina
🇦🇷
Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

and more 310 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy